A drug targeting mRNA essential for APO C-III production provided a 50% reduction in triglycerides in BRIDGE-TIMI 73a, the largest ever observed in a controlled trial.
In patients with HFpEF and obesity, symptom reduction and weight loss provided by semaglutide extends to those with diabetes, suggest new data from the STEP-HFpEF DM trial.
Chelation therapy to remove potentially toxic levels of lead was not associated with a reduction in CV events in post-MI patients with diabetes in the TACT2 trial.